Atherosclerosis
Volume 205, Issue 1 , Pages 202-206 , July 2009

Effect of simvastatin on kidney function loss in patients with coronary heart disease: Findings from the Scandinavian Simvastatin Survival Study (4S)

  • Janna Huskey

      Affiliations

    • University of Colorado Health Sciences Center, Division of Renal Diseases and Hypertension; Denver, CO, USA
    • ,
  • Joann Lindenfeld

      Affiliations

    • University of Colorado Health Sciences Center, Division of Cardiology, Aurora, CO, USA
    • ,
  • Thomas Cook

      Affiliations

    • Merck Research Laboratories, Rahway, NJ, USA
    • ,
  • Giovanni Targher

      Affiliations

    • Section of Endocrinology, Department of Biomedical and Surgical Sciences, University Hospital, Verona, Italy
    • ,
  • Jessica Kendrick

      Affiliations

    • University of Colorado Health Sciences Center, Division of Renal Diseases and Hypertension; Denver, CO, USA
    • ,
  • John Kjekshus

      Affiliations

    • Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway
    • ,
  • Terje Pedersen

      Affiliations

    • Centre for Preventative Medicine, Ulleval University Hospital, Oslo, Norway
    • ,
  • Michel Chonchol

      Affiliations

    • University of Colorado Health Sciences Center, Division of Renal Diseases and Hypertension; Denver, CO, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 303 399 6997; fax: +1 303 399 3131.

Received 27 August 2008 ,Revised 24 October 2008 ,Accepted 5 November 2008.

References 

  1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusck JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  3. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006;1:229–235
  4. Menon V, Sarnak MJ. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis. 2005;45:223–232
  5. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int. 2000;57(suppl 75):S27–S31
  6. Kasiske BL, O’Donnell MP, Kim Y, Keane WF. Treatment of hyperlipidemia in chronic progressive renal disease. Curr Opin Nephrol Hypertens. 1993;12:602–608
  7. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246–1261
  8. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  9. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary artery disease. Circulation. 2005;112:171–178
  10. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57:728–734
  11. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  12. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC . Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605–1613
  13. Agarwal R. Effects of statins on renal function. Mayo Clin Proc. 2007;82:1381–1390
  14. Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993;71:393–400
  15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  16. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  17. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart protection study collaborative group: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  18. Shepherd J, Kastelein J, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study. Clin J Am Soc Nephrol. 2007;2:1131–1139
  19. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ. 2008;336:645–651
  20. Hidekazu I, Takashi K, Yamashita S, Hiramatsu N, Maeshima A, Kaneko Y, et al. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulo-interstitial fibrosis. Nephron Exp Nephrol. 2004;97:e115–e122
  21. Kim SY, Guijarro C, O’Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int. 1995;48:363–371
  22. Miyazaki K, Isbel NM, Lan HY, Hattori M, Ito K, Bacher M, et al. Up-regulation of macrophage colony-stimulating factor and monocyte recruitment during lipid-induced glomerular injury in the exogenous hypercholesterolemic rats. Clin Exp Immunol. 1997;108:318–323
  23. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme reductase inhibitor, improves endothelial function within one month. Circulation. 1997;95:1126–1131
  24. Fuiano G, Esposito C, Sepe V, Colucci G, Bovino M, Rosa M, et al. Effects of hypercholesterolemia of renal hemodynamics: study in patients with nephrotic syndrome. Nephron. 1996;73:430–435
  25. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of e-NOS and oxidant stress. Hypertension. 2004;44:186–190

PII: S0021-9150(08)00792-2

doi: 10.1016/j.atherosclerosis.2008.11.010

Atherosclerosis
Volume 205, Issue 1 , Pages 202-206 , July 2009

Article Tools

* Image Usage & Resolution